HLB Life Science Co Ltd

Chart & Performance

D1W1MN

P/E

85.41

P/S

5.13

EPS

60.30

Div Yield, %

—

Shrs. gr., 5y

11.36%

Rev. gr., 5y

-2.16%

Revenues

102.24b

+4.34%

Net income

6.14b

CFO

-32.01b

L+219.54%

Earnings

Aug 12, 2025

Profile

HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors; Seclidemstat, a novel epigenetic oral small molecule for target therapy to normalize gene expression and suppress tumor growth in various solid tumors, such as lung, breast, and prostate cancer; and Tegavivint, inhibitor of the Wnt/Ã-catenin for the treatment of desmoid tumors, acute myeloid leukemia, osteosarcoma, and a range of solid tumor types. In addition, the company develops LifeLiver, an extracorporeal bioartificial liver system; HepaStem, a heterologous human adult liver-derived progenitor cell therapy; and HLBLS-200, a biocompatible polysaccharide-based powders that forms adhesive hemostasis upon contact with blood. Further, it is involved in the waste heat recovery, cogeneration power generation, facility installation, solar energy, photovoltaic power generation, bioenergy, geothermal energy, waste energy, wind power, and fuel cell businesses. The company also undertakes energy efficiency projects; and builds heating/heating system improvement projects. The company was formerly known as Energy Solutions Co., Ltd. and changed its name to HLB Life Science Co.,Ltd. in December 2015. HLB Life Science Co.,Ltd. was founded in 1998 and is headquartered in Hwaseong, South Korea.

URL

http://www.hlb-ls.com/

IPO date

Nov 25, 2008

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	102,240,056 4.34%	97,990,441 -1.61%	99,591,376 86.17%
Cost of revenue	114,606,922	109,726,265	112,298,914
Unusual Expense (Income)
NOPBT	(12,366,866)	(11,735,824)	(12,707,539)
NOPBT Margin
Operating Taxes	(3,057,595)	(590,063)	(6,479,000)
Tax Rate
NOPAT	(9,309,271)	(11,145,761)	(6,228,539)
Net income	6,137,882 -202.58%	(5,983,400) -88.98%	(54,277,435) 10.43%
Dividends
Dividend yield
Proceeds from repurchase of equity	72,171,520	(679,971)	459,369
BB yield		0.05%	-0.04%
Debt
Debt current	41,060,258	114,743,482	10,452,100
Long-term debt	83,547,713	53,180,367	137,021,270
Deferred revenue		8	832,407
Other long-term liabilities	1,612,968	1,651,784	1,884,492
Net debt	(183,008,933)	(56,973,768)	(51,298,960)
Cash flow
Cash from operating activities	(32,005,464)	(10,015,987)	(29,743,908)
CAPEX	(27,295,501)	(20,618,342)	(11,653,558)
Cash from investing activities	(37,781,396)	(8,882,725)	(72,643,336)
Cash from financing activities	105,743,546	4,785,941	102,096,453
FCF	(24,905,132)	(34,956,620)	(85,245,005)
Balance
Cash	79,565,918	78,859,684	131,440,944
Long term investments	228,050,986	146,037,933	67,331,386
Excess cash	302,504,901	219,998,094	193,792,761
Stockholders' equity	78,273,150	89,198,811	41,222,654
Invested Capital	445,947,632	310,243,408	344,069,725
ROIC
ROCE
EV
Common stock shares outstanding		109,199	100,970
Price	10,010.00 -12.58%	11,450.00 8.02%	10,600.00 -14.86%
Market cap		1,250,333,622 16.82%	1,070,284,682 -13.47%
EV		1,219,222,502	1,020,327,420
EBITDA	(6,466,293)	(4,039,834)	(7,736,930)
EV/EBITDA
Interest	16,819,174	21,650,382	9,870,396
Interest/NOPBT